Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene auto...
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 7, 2025
Q1 2025
May 8, 2025